Evercore ISI Group Initiates Coverage on Theravance Biopharma Inc(NASDAQ:TBPH). The shares have been rated Buy. The rating by Evercore ISI Group was issued on Aug 29, 2016.
In a different note, On Aug 3, 2016, Bank of America said it Downgrades its rating on Theravance Biopharma Inc. The shares have been rated ‘Underperform’ by the firm. Guggenheim Securities said it Initiates Coverage on Theravance Biopharma Inc, according to a research note issued on Jun 20, 2016. The shares have been rated ‘Buy’ by the firm.
Theravance Biopharma Inc (TBPH) made into the market gainers list on Thursdays trading session with the shares advancing 1.76% or 0.5 points. Due to strong positive momentum, the stock ended at $28.86, which is also near the day’s high of $29.15. The stock began the session at $28.26 and the volume stood at 2,21,527 shares. The 52-week high of the shares is $29.15 and the 52 week low is $10.56. The company has a current market capitalization of $1,381 M and it has 4,78,51,848 shares in outstanding.
Theravance Biopharma Inc(TBPH) last announced its earnings results on Aug 8, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $5.47M. Analysts had an estimated revenue of $12.73M. Earnings per share were $-1.06. Analysts had estimated an EPS of $-1.05.
Several Insider Transactions has been reported to the SEC. On Aug 25, 2016, Brett K Haumann (SVP Clin Dev & Chief Med Ofc) sold 4,491 shares at $27.99 per share price.Also, On Aug 22, 2016, Bradford J Shafer (EVP, Gen. Counsel, Secretary) sold 49,122 shares at $27.95 per share price.On Mar 15, 2016, Plc Glaxosmithkline (10% owner) purchased 1,301,015 shares at $17.70 per share price, according to the Form-4 filing with the securities and exchange commission.
Theravance Biopharma Inc. (Theravance Biopharma) is a biopharmaceutical company. The Company is engaged to create value from a diverse set of assets: an approved product; a development pipeline of mid- and late-stage assets and a productive research platform designed for long-term growth. VIBATIV (telavancin) its commercial product is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. TD-4208 is an investigational long-acting muscarinic antagonist (LAMA) being developed as a potential once-daily nebulized treatment for chronic obstructive pulmonary disease (COPD). Axelopran (TD-1211) is an investigational potential once-daily oral treatment for opioid-induced constipation (OIC). Its earlier-stage clinical assets represent approaches for potentially treating diseases of the lung and gastrointestinal tract and infectious disease.